-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
A few days ago, the Tübingen-based biopharmaceutical company CureVac revealed in its latest financial report that the company’s lung cancer project with the German biotechnology company Boehringer has been terminated
This move ends the 500 million euro exclusive therapeutic exploration and development partnership that the two parties signed seven years ago
However, in a brief statement in CureVac's financial statements, CureVac stated that it had terminated the cooperation agreement in June this year, and it is expected that the entire termination process of the cooperation will be completed in November 2021
In 2014, Boehringer Ingelheim and CureVac jointly announced an exclusive global licensing and R&D cooperation agreement to jointly develop CureVac's early clinical development stage, a therapeutic vaccine for the treatment of lung cancer, CV9202
Dr.
Although it did not specify the reason for the termination of the cooperation, CureVac added that the company is developing a "legacy project" that uses an old protamine formula developed seven years ago
According to the final results of the vaccine released by Curevac, the average protection rate of Curevac vaccine for all age groups is about 47%
It seems that it is also affected by the poor test data.
According to the financial report, CureVac's second-quarter revenue was only 22.
Reference source: Boehringer, CureVac Terminate Lung Cancer Project on Poor Performance
